Takeda’s Inflammatory Bowel Disease Drug Approved for U.S. Sale

May 20, 2014 9:15 PM

24 0

Takeda Pharmaceutical Co. (4502) won approval from U.S. regulators for a treatment against the two most common inflammatory bowel diseases.

The drug, Entyvio, also known as vedolizumab, was cleared for adults with moderate to severe ulcerative colitis and moderate to severe Crohn’s disease, the Food and Drug Administration said today in a statement.

Read more

To category page